Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis : a clinical and imaging study of abatacept (the ADJUST trial).

Emery, P;Durez, Patrick;Dougados, M;Legerton, C W;Westhovens, R;et.al.
(2010) Annals of the Rheumatic Diseases — Vol. 69, n° 3, p. 510-516 (2010)

Files

pdfdocument.pdf
  • Open Access
  • Adobe PDF
  • 267.48 KB
Download

Details

Authors
  • Emery, P
    Author
  • Durez, PatrickUCLouvain
    Author
  • Dougados, M
    Author
  • Legerton, C W
    Author
  • Westhovens, R
    Author
Show more
Abstract
Several agents provide treatment for established rheumatoid arthritis (RA), but a crucial therapeutic goal is to delay/prevent progression of undifferentiated arthritis (UA) or very early RA.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Emery, P., Durez, P., Dougados, M., Legerton, C. W., Becker, J.-C., Vratsanos, G., Genant, H. K., Peterfy, C., Mitra, P., Overfield, S., Qi, K., & Westhovens, R. (2010). Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis : a clinical and imaging study of abatacept (the ADJUST trial). Annals of the Rheumatic Diseases, 69(3), 510-516. https://doi.org/10.1136/ard.2009.119016 (Original work published 2010)